1. Home
  2. NAMS vs HWKN Comparison

NAMS vs HWKN Comparison

Compare NAMS & HWKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • HWKN
  • Stock Information
  • Founded
  • NAMS 2019
  • HWKN 1938
  • Country
  • NAMS Netherlands
  • HWKN United States
  • Employees
  • NAMS N/A
  • HWKN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • HWKN Specialty Chemicals
  • Sector
  • NAMS Health Care
  • HWKN Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • HWKN Nasdaq
  • Market Cap
  • NAMS 2.7B
  • HWKN 2.4B
  • IPO Year
  • NAMS N/A
  • HWKN N/A
  • Fundamental
  • Price
  • NAMS $18.57
  • HWKN $104.41
  • Analyst Decision
  • NAMS Strong Buy
  • HWKN Hold
  • Analyst Count
  • NAMS 7
  • HWKN 1
  • Target Price
  • NAMS $41.33
  • HWKN $122.00
  • AVG Volume (30 Days)
  • NAMS 646.5K
  • HWKN 161.7K
  • Earning Date
  • NAMS 03-04-2025
  • HWKN 01-29-2025
  • Dividend Yield
  • NAMS N/A
  • HWKN 0.69%
  • EPS Growth
  • NAMS N/A
  • HWKN 12.32
  • EPS
  • NAMS N/A
  • HWKN 3.91
  • Revenue
  • NAMS $33,594,000.00
  • HWKN $952,133,000.00
  • Revenue This Year
  • NAMS $131.53
  • HWKN $6.21
  • Revenue Next Year
  • NAMS N/A
  • HWKN $5.81
  • P/E Ratio
  • NAMS N/A
  • HWKN $26.71
  • Revenue Growth
  • NAMS 78.77
  • HWKN 3.01
  • 52 Week Low
  • NAMS $15.19
  • HWKN $67.85
  • 52 Week High
  • NAMS $27.29
  • HWKN $139.55
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 29.65
  • HWKN 36.40
  • Support Level
  • NAMS $18.88
  • HWKN $109.62
  • Resistance Level
  • NAMS $20.46
  • HWKN $112.49
  • Average True Range (ATR)
  • NAMS 1.11
  • HWKN 3.72
  • MACD
  • NAMS -0.09
  • HWKN -0.37
  • Stochastic Oscillator
  • NAMS 5.84
  • HWKN 7.26

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HWKN Hawkins Inc.

Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers.

Share on Social Networks: